Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Bendamustine Action Pathway
Homo sapiens
Drug Action Pathway
Created: 2023-08-02
Last Updated: 2023-11-27
Bendamustine is a nitrogen mustard used as an antineoplastic in chemotherapy. It is indicated to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed passed the treatment with rituximab. This drug is derived from another alkylating agent named mechlorethamine. As an alkylating agent, bendamustine causes bifunctional crosslinking between DNA bases. It is bifunctional because it can trigger intra- and inter-strand crosslinks. This prevents the replication and the transcription of the DNA. The general mechanism of action is unknown but those crosslinks in the DNA seem to result in cell death. This drug is able to do those crosslinks in quiescent or active cells. Bendamustine is administered as an intravenous or parenteral injection.
References
Bendamustine Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Hartmann JT, Mayer F, Schleicher J, Horger M, Huober J, Meisinger I, Pintoffl J, Kafer G, Kanz L, Grunwald V: Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer. 2007 Aug 15;110(4):861-6. doi: 10.1002/cncr.22846.
Pubmed: 17599772
Dennie TW, Kolesar JM: Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther. 2009;31 Pt 2:2290-311. doi: 10.1016/j.clinthera.2009.11.031.
Pubmed: 20110042
Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP: Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54. doi: 10.1007/s00280-015-2727-6. Epub 2015 Apr 1.
Pubmed: 25829094
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings